Evidence map›Paper›PMID 27394167›Full record

ArticlePharmacological research2016

A pyruvate decarboxylase-mediated therapeutic strategy for mimicking yeast metabolism in cancer cells.

Bronwyn Scott, Jianliang Shen, Sara Nizzero, Kathryn Boom, Stefano Persano, Yu Mi, Xuewu Liu, Yuliang Zhao, Elvin Blanco, Haifa Shen and 2 more

Open access · greenAbstract read
In one paragraph

Article in Pharmacological research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Contribution of Kupffer cells to liposome accumulation in the liver.Colloids and surfaces. B, Biointerfaces · 2017
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Bronwyn ScottDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Jianliang ShenDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Sara NizzeroDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA; Applied Physics Graduate Program, Rice University, Houston, TX 77005, USA.
Kathryn BoomDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Stefano PersanoDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Yu MiDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Xuewu LiuDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Yuliang ZhaoCAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, National Center for Nanoscience & Technology of China, University of Chinese Academy of Sciences, Beijing 100190, China; Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China.
Elvin BlancoDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Haifa ShenDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA; Department of Cell and Developmental Biology, Weill Cornell Medicine, New York, NY 10065, USA.
Mauro FerrariDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA; Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA. Electronic address: mferrari@houstonmethodist.org.
Joy WolframDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA; CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, National Center for Nanoscience & Technology of China, University of Chinese Academy of Sciences, Beijing 100190, China. Electronic address: jvwolfram@houstonmethodist.org.
Houston Methodist · USUniversity of Chinese Academy of Sciences · CNWeill Cornell Medicine · US

Funding

Texas Center for Cancer NanomedicineU54CA151668 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FERRARI, MAURO · 2010 to 2014
$12.4M
TRANS-NETWORK PROJECTSU54CA143837 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FERRARI, MAURO · 2009 to 2014
$10.8M
NCI NIH HHS U54 CA143837NCI NIH HHS U54 CA151668
6 · The paper itself

Abstract

Cancer cells have high rates of glycolysis and lactic acid fermentation in order to fuel accelerated rates of cell division (Warburg effect). Here, we present a strategy for merging cancer and yeast metabolism to remove pyruvate, a key intermediate of cancer cell metabolism, and produce the toxic compound acetaldehyde. This approach was achieved by administering the yeast enzyme pyruvate decarboxylase to triple negative breast cancer cells. To overcome the challenges of protein delivery, a nanoparticle-based system consisting of cationic lipids and porous silicon were employed to obtain efficient intracellular uptake. The results demonstrate that the enzyme therapy decreases cancer cell viability through production of acetaldehyde and reduction of lactic acid fermentation.

Indexed as

AcetaldehydeAntineoplastic AgentsCell Line, TumorCell SurvivalDrug CarriersDrug CompoundingEnergy MetabolismFemaleFermentationGlycolysisHumansLactic AcidLipidsNanoparticlesPorosityPyruvate DecarboxylaseAcetaldehydeAntineoplastic AgentsDrug CarriersLactic AcidLipidsPyruvate DecarboxylaseSaccharomyces cerevisiae ProteinsSiliconCancer metabolismMultistage vectorNanotechnologyPyruvate decarboxylaseWarburg effect

Identifiers

PMID27394167
PMCPMC5026593
OpenAlexW2468779433

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.